Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Rev Sci Instrum ; 95(6)2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38921057

ABSTRACT

Magnetic nanoparticles (MNPs) are used extensively across numerous disciples, with applications including Magnetic Particle Imaging (MPI), targeted hyperthermia, deep brain stimulation, immunoassays, and thermometry. The assessment of MNPs, especially those being designed for MPI, is performed with magnetic particle spectrometers, relaxometers, loop tracers, or similar devices. Despite the many applications and the need for particle assessment, there are few consolidated resources for designing or building such a MNP assessment system. Here, we describe the design and performance of an open-source device capable of spectroscopy, relaxometry, and loop tracing. We show example measurements from the device and quantify the detection sensitivity by measuring a dilution series of Synomag-D 70 nm (from 0.5 mg Fe/ml to 7 ng Fe/ml) with a 10 mT drive field at 23.8 kHz. The device measures 260 pg Fe with SNR = 1 and 1.3 ng at SNR = 5 in spectroscopy mode in under one second of measurement time. The system has a dynamic range of 60 µg to 260 pg Fe without changing the hardware configuration. As an example application, we characterize Synomag-D's relaxation time constant for drive fields 2-18 mT and compare the magnetization responses of two commonly used MNPs.

2.
Neuropharmacology ; 63(6): 1051-63, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22796107

ABSTRACT

Estrogen acts through two molecularly distinct receptors termed estrogen receptor alpha (ERα) and estrogen receptor beta (ERß) which bind estradiol with similar affinities and mediate the effects of estrogen throughout the body. ERα plays a major role in reproductive physiology and behavior, and mediates classic estrogen signaling in such tissues as the uterus, mammary gland, and skeleton. ERß, however, modulates estrogen signaling in the ovary, the immune system, prostate, gastrointestinal tract, and hypothalamus, and there is some evidence that ERß can regulate ERα activity. Moreover, ERß knockout studies and receptor distribution analyses in the CNS suggest that this receptor may play a role in the modulation of mood and cognition. In recent years several ERß-specific compounds (selective estrogen receptor beta modulators; SERM-beta) have become available, and research suggests potential utility of these compounds in menopausal symptom relief, breast cancer prevention, diseases that have an inflammatory component, osteoporosis, cardiovascular disease, and inflammatory bowel disease, as well as modulation of mood, and anxiety. Here we demonstrate an antidepressant-like effect obtained using two SERM-beta compounds, SERM-beta1 and SERM-beta2. These compounds exhibit full agonist activity at ERß in a cell based estrogen response element (ERE) transactivation assay. SERM-beta1 and 2 are non-proliferative with respect to breast as determined using the MCF-7 breast cancer cell-based assay and non-proliferative in the uterus as determined by assessing the effects of SERM-beta compounds on immature rat uterine weight and murine uterine weight. In vivo SERM-beta1 and 2 are brain penetrant and display dose dependent efficacy in the murine dorsal raphe assays for induction of tryptophan hydroxylase mRNA and progesterone receptor protein. These compounds show activity in the murine forced swim test and promote hippocampal neurogenesis acutely in rats. Taken together these data suggest that ERß may play an important role in modulating mood and the ERß specific compounds described herein will be useful tools for probing the utility of an ERß agonist for treating neuroendocrine-related mood disturbance and menopausal symptoms.


Subject(s)
Antidepressive Agents , Estrogen Receptor beta/drug effects , RNA, Messenger/biosynthesis , Raphe Nuclei/enzymology , Selective Estrogen Receptor Modulators/pharmacology , Swimming/psychology , Tryptophan Hydroxylase/biosynthesis , Animals , Blood-Brain Barrier/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , DNA/genetics , Dose-Response Relationship, Drug , Estrogen Receptor alpha/drug effects , Female , Hippocampus/drug effects , Hippocampus/growth & development , Humans , Immunohistochemistry , In Situ Hybridization , Neurogenesis/drug effects , Organ Size/drug effects , Plasmids/genetics , RNA, Messenger/genetics , Rats , Rats, Sprague-Dawley , Receptors, Androgen/metabolism , Receptors, Progesterone/metabolism , Transcriptional Activation/drug effects , Tryptophan Hydroxylase/genetics , Uterus/anatomy & histology , Uterus/physiology
3.
J Foot Surg ; 22(1): 45-9, 1983.
Article in English | MEDLINE | ID: mdl-6643927

ABSTRACT

Dislocation fracture of the tarsometatarsal joint is a rare but devastating injury that presents a great challenge to the podiatric surgeon. A case of Lisfranc's dislocation is presented that was further complicated by the 7-month interval between injury and diagnosis. Because of this interval and the resultant degenerative change that ensued in the tarsometatarsal articulation, surgical arthrodesis of these joints was attempted with combined use of bone screws and Kirschner wire internal fixation. Results of surgery were excellent with anatomical realignment of Lisfranc's articulation and the return of all preinjury physical activities 8 months postoperatively.


Subject(s)
Arthrodesis , Joint Dislocations/surgery , Tarsal Joints/injuries , Aged , Fracture Fixation, Internal , Fractures, Bone/surgery , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...